Charles Schwab’s Longboard Pharmaceuticals, Inc. Common Stock LBPH Stock Holding History

Charles Schwab’s Portfolio LBPH Stock Details LBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-260,721	Closed	-$8.69M	–	3559
2024 Q3	$8.69M	Buy	260,721 +173,053	+197%	+$5.96M	﹤0.01%	2094
2024 Q2	$2.37M	Buy	87,668 +20,027	+30%	+$395K	﹤0.01%	2651
2024 Q1	$1.46M	Buy	67,641 +24,708	+58%	+$539K	﹤0.01%	2682
2023 Q4	$259K	Hold	42,933	–	–	﹤0.01%	3243
2023 Q3	$239K	Hold	42,933	–	–	﹤0.01%	3253
2023 Q2	$315K	Buy	+42,933	New	+$325K	﹤0.01%	3215

Charles Schwab's LBPH Position: Q4 2024 in Review

Charles Schwab sold out of Longboard Pharmaceuticals, Inc. Common Stock (LBPH) in Q4 2024, closing a stake of 260,721 shares — an estimated $8.69M sold.

Charles Schwab first reported a position in LBPH in Q2 2023 and held it in 6 quarters. The position peaked at $8.69M in Q3 2024. 0 funds tracked by Wall St. Rank hold LBPH as of Q4 2024.

Charles Schwab reported no remaining Longboard Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Charles Schwab sold 260,721 Longboard Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $8.69M.
Charles Schwab first reported a position in Longboard Pharmaceuticals, Inc. Common Stock in Q2 2023 and held it in 6 quarters.
Charles Schwab's Longboard Pharmaceuticals, Inc. Common Stock position peaked at $8.69M in Q3 2024.
0 funds tracked by Wall St. Rank held Longboard Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on Charles Schwab's 13F filing for Q4 2024, filed 6 Feb 2025.